Chemical Peptide Synthesis

This is a Notice of Intent, not a request for quote. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with GenScript, 120 Centennial Ave, Piscataway, NJ 08854 to procure qty. of 1 Chemical Peptide Synthesis which will be used to express the antibody proteins. The antibodies are novel and are not commercially available, therefore, require custom gene synthesis to fill an anticipative repetitive need for supplies. These antibodies will be screened for malaria inhibitory activity and specificity. In order to evaluate these antibodies and define their specificity, The Laboratory of Cellular Immunology under the supervision of Robert Seder, MD, will need to synthesize, clone and express these novel antibody sequences and evaluate their function and evaluate their function both in vitro and in vivo. Place of delivery is Bethesda, MD 20892. The statutory authority for this sole source requirement is 41 U.S.C. 253 (c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply will satisfy agency requirements. THIS IS NOT A REQUEST FOR QUOTES. All responsible sources that could provide comparable supplies may submit a capability statement that will be considered by email (subject line to reference NIAID-NOI-17-1864331) to Chantal Guetat at chantal.guetat@nih.gov, by 5:00 pm eastern standard Wednesday, September 6, 2017. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.